Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
03 2019
Historique:
received: 08 01 2019
accepted: 17 01 2019
entrez: 6 3 2019
pubmed: 6 3 2019
medline: 18 4 2019
Statut: ppublish

Résumé

Cost-effectiveness models that present results in terms of cost per quality-adjusted life-year for health technologies are used to inform policy decisions in many parts of the world. Health state utilities (HSUs) are required to calculate the quality-adjusted life-years. Even when clinical studies assessing the effectiveness of health technologies collect data on HSUs to populate a cost-effectiveness model, which rarely happens, analysts typically need to identify at least some additional HSUs from alternative sources. When possible, HSUs are identified by a systematic review of the literature, but, again, this rarely happens. In 2014, ISPOR established a Good Practices for Outcome Research Task Force to address the use of HSUs in cost-effectiveness models. This task force report provides recommendations for researchers who identify, review, and synthesize HSUs for use in cost-effectiveness models; analysts who use the results in models; and reviewers who critically appraise the suitability and validity of the HSUs selected for use in models. The associated Minimum Reporting Standards of Systematic Review of Utilities for Cost-Effectiveness checklist created by the task force provides criteria to judge the appropriateness of the HSUs selected for use in cost-effectiveness models and is suitable for use in different international settings.

Identifiants

pubmed: 30832964
pii: S1098-3015(19)30051-8
doi: 10.1016/j.jval.2019.01.004
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

267-275

Informations de copyright

Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

John Brazier (J)

University of Sheffield, Sheffield, South Yorkshire, UK. Electronic address: j.e.brazier@sheffield.ac.uk.

Roberta Ara (R)

University of Sheffield, Sheffield, South Yorkshire, UK.

Ismail Azzabi (I)

Takeda Pharmaceutical International AG, Zurich, Switzerland.

Jan Busschbach (J)

Erasmus University Medical Center, Rotterdam, The Netherlands; Viersprong Institute for Studies of Personality Disorders, Halsteren, The Netherlands.

Hélène Chevrou-Séverac (H)

Celgene International Sàrl, Boudry, Switzerland.

Bruce Crawford (B)

APAC, Syneos Health, Tokyo, Japan.

Luciane Cruz (L)

Health Technology Assessment Institute, Federal University of Rio Grande du Sol, Porto Alegre, Brazil.

John Karnon (J)

The University of Adelaide, Adelaide, Australia.

Andrew Lloyd (A)

Acaster Lloyd Consulting Ltd, Oxford, UK.

Suzy Paisley (S)

University of Sheffield, Sheffield, South Yorkshire, UK.

A Simon Pickard (AS)

Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH